Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Beacon Therapeutics Reports Positive Phase 2 Results for Gene Therapy in X-Linked Retinitis Pigmentosa

Summary by ophthalmologytimes.com
In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

ophthalmologytimes.comophthalmologytimes.com

Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa

In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.

Read Full Article
modernretina.commodernretina.com

Beacon Therapeutics announces positive topline data from DAWN and SKYLINE trials

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

modernretina.com broke the news in on Monday, September 8, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Beacon icon

Beacon

News
For You
SearchBlindspotLocal